Gene · 1848
Papers2,747
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,747
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Scoparone attenuates PD-L1 expression in human breast cancer cells by MKP-3 upregulation. | Anim Cells Syst (Seoul) | 2024 | 38348341 | PubTator, text mining | PubMed |
| Effects of sex and gender on the etiologies and presentation of select internalizing psychopathologies. | Transl Psychiatry | 2024 | 38307846 | PubTator, text mining | PubMed |
| Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance. | Exp Hematol Oncol | 2024 | 38291542 | PubTator, text mining | PubMed |
| The Role of SOX2 and SOX9 in Radioresistance and Tumor Recurrence. | Cancers (Basel) | 2024 | 38275880 | PubTator, text mining | PubMed |
| Identifying novel gene dysregulation associated with opioid overdose death: A meta-analysis of differential gene expression in human prefrontal cortex. | medRxiv | 2024 | 38260365 | PubTator, text mining | PubMed |
| ERK2 Is a Promoter of Cancer Cell Growth and Migration in Colon Adenocarcinoma. | Antioxidants (Basel) | 2024 | 38247543 | PubTator, text mining | PubMed |
| KLF9‑regulated FBXO31 inhibits the progression of endometrial cancer and enhances the sensitivity of endometrial cancer cells to cisplatin. | Exp Ther Med | 2024 | 38234628 | PubTator, text mining | PubMed |
| Spatial transcriptomic interrogation of the tumour-stroma boundary in a 3D engineered model of ameloblastoma. | Mater Today Bio | 2024 | 38226014 | PubTator, text mining | PubMed |
| Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Nat Commun | 2024 | 38216572 | PubTator, text mining | PubMed |
| FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degradation. | Cell Death Dis | 2024 | 38216561 | PubTator, text mining | PubMed |
| Accelarated immune ageing is associated with COVID-19 disease severity. | Immun Ageing | 2024 | 38212801 | PubTator, text mining | PubMed |
| Distinct mesenchymal cell states mediate prostate cancer progression. | Nat Commun | 2024 | 38191471 | PubTator, text mining | PubMed |
| ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma. | Oncogene | 2024 | 38066089 | PubTator, text mining | PubMed |
| First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. | Eur J Cancer | 2024 | 38039779 | PubTator, text mining | PubMed |
| Global Transcriptome Analysis Reveals Distinct Phases of the Endothelial Response to TNF. | J Immunol | 2024 | 38019121 | PubTator, text mining | PubMed |
| Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. | Nat Cancer | 2024 | 37814010 | PubTator, text mining | PubMed |
| Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers. | Oncologist | 2024 | 37616543 | PubTator, text mining | PubMed |
| The MORC2 p.S87L mutation reduces proliferation of pluripotent stem cells derived from a patient with the spinal muscular atrophy-like phenotype by inhibiting proliferation-related signaling pathways. | Neural Regen Res | 2024 | 37488868 | PubTator, text mining | PubMed |
| Single-cell sequencing reveals the evolution of immune molecules across multiple vertebrate species. | J Adv Res | 2024 | 36871615 | PubTator, text mining | PubMed |
| Characterizing the secretome of EGFR mutant lung adenocarcinoma. | Front Oncol | 2023 | 38260835 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1848/papers?page=7